Text Size

10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00885612
First received: April 21, 2009
Last updated: June 28, 2010
Last verified: June 2010
History of Changes

April 21, 2009
June 28, 2010
May 2009
March 2010   (final data collection date for primary outcome measure)
The primary objective of this study is to define 10-year CHD risk according to Framingham risk score in postmenopausal early breast cancer patients who are taking aromatase inhibitors as an adjuvant treatment. [ Time Frame: 1 visit ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00885612 on ClinicalTrials.gov Archive Site
  • To describe 10-year CHD risk comparing to the historical data of 10-year cancer-specific mortality in breast cancer [ Time Frame: 1 Visit ] [ Designated as safety issue: No ]
  • To analyse CHD management patterns according to defined 10-year CHD risk categories [ Time Frame: 1 Visit ] [ Designated as safety issue: No ]
  • To describe correlation between concommitant medication(Anthracycline, Trasuzumab) and CHD risk [ Time Frame: 1 Visit ] [ Designated as safety issue: No ]
  • To describe 10-year CHD risk comparing to the historical data of 10-year cancer-specific mortality in breast cancer [ Time Frame: 1 Visit ] [ Designated as safety issue: No ]
  • To analyse the management patterns of patients according to defined 10-year CHD risk categories [ Time Frame: 1 Visit ] [ Designated as safety issue: No ]
  • To describe correlation between concommitant medication(Anthracycline, Trasuzumab) and CHD risk [ Time Frame: 1 Visit ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)
10-year CHD Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer Patients Taking Aromatase Inhibitors

10-year CHD risk evaluation and its treatment pattern analysis in postmenopausal early breast cancer patients taking aromatase inhibitors.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Probability Sample

Postmenopausal patients with early breast cancer, who are taking aromatase inhibitors no longer than 6 months as an adjuvant treatment after surgery
Breast Cancer
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1114
March 2010
March 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Early Breast Cancer patients
  • Postmenopausal Status
  • patients taking Aromatase Inhibitor as adjuvant treatment no longer than 6 months

Exclusion Criteria:

  • Advanced Breast Cancer patients(stage iii, iv)
  • Patients who are hard to be analysed by limitation of chart record according to investigators discretion
  • patients who already have been registered in this study
Female
50 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT00885612
NIS-OKR-DUM-2009/1
No
MC MD, AstraZeneca
AstraZeneca
Not Provided
Study Director: JoonWoo Bahn, MD, PhD AstraZeneca Korea
AstraZeneca
June 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP